HomeCompareNUAN vs JNJ

NUAN vs JNJ: Dividend Comparison 2026

NUAN yields 3.57% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $5.1K in total portfolio value· pulled ahead in Year 9
10 years
NUAN
NUAN
● Live price
3.57%
Share price
$55.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.2K
Annual income
$449.44
Full NUAN calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — NUAN vs JNJ

📍 JNJ pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNUANJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NUAN + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NUAN pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NUAN
Annual income on $10K today (after 15% tax)
$303.63/yr
After 10yr DRIP, annual income (after tax)
$382.02/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,603.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NUAN + JNJ for your $10,000?

NUAN: 50%JNJ: 50%
100% JNJ50/50100% NUAN
Portfolio after 10yr
$27.7K
Annual income
$2,569.42/yr
Blended yield
9.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NUAN
Analyst Ratings
8
Buy
8
Hold
1
Sell
Consensus: Buy
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NUAN buys
0
JNJ buys
0
No recent congressional trades found for NUAN or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNUANJNJ
Forward yield3.57%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$25.2K$30.3K
Annual income after 10y$449.44$4,689.40
Total dividends collected$4.1K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: NUAN vs JNJ ($10,000, DRIP)

YearNUAN PortfolioNUAN Income/yrJNJ PortfolioJNJ Income/yrGap
1$11,057$357.21$10,592$272.30+$465.00NUAN
2$12,200$369.13$11,289$357.73+$911.00NUAN
3$13,435$380.65$12,123$472.89+$1.3KNUAN
4$14,767$391.75$13,141$629.86+$1.6KNUAN
5$16,203$402.42$14,408$846.81+$1.8KNUAN
6$17,750$412.67$16,021$1,151.60+$1.7KNUAN
7$19,415$422.49$18,122$1,588.22+$1.3KNUAN
8$21,206$431.89$20,930$2,228.20+$276.00NUAN
9← crossover$23,132$440.87$24,792$3,191.91$1.7KJNJ
10$25,200$449.44$30,274$4,689.40$5.1KJNJ

NUAN vs JNJ: Complete Analysis 2026

NUANStock

Nuance Communications, Inc. provides conversational and cognitive artificial intelligence (AI) innovations that bring intelligence to everyday work and life. The company delivers solutions that understand, analyze, and respond to people - amplifying human intelligence to increase productivity and security. Its Healthcare segment provides clinical speech and clinical language understanding solutions that improve the clinical documentation process, from capturing the complete patient record to improving clinical documentation and quality measures for reimbursement. Its solutions include Dragon Medical One, cloud-based speech solution; computer-assisted physician documentation; diagnostic imaging solutions; Nuance Dragon Ambient eXperience, a voice-enabled solution; and clinical documentation improvement and coding. The company's Enterprise segment primarily engages in using speech, natural language understanding, and artificial intelligence to provide automated customer solutions and services for voice, mobile, web, and messaging channels. Its solutions include intelligent engagement solutions; Conversational AI; Engagement AI; and Security AI. Its Other segment provides voicemail transcription services. It serves organizations across healthcare, financial services, telecommunications, government, and retail. The company markets and sells its solutions and technologies directly through sales force, as well as through a network of resellers, including system integrators, independent software vendors, value-added resellers, distributors, hardware vendors, telecommunications carriers, and e-commerce Websites worldwide. The company was formerly known as ScanSoft, Inc. and changed its name to Nuance Communications, Inc. in October 2005. Nuance Communications, Inc. was incorporated in 1992 and is headquartered in Burlington, Massachusetts. As of March 4, 2022, Nuance Communications, Inc. operates as a subsidiary of Microsoft Corporation.

Full NUAN Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this NUAN vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NUAN vs SCHDNUAN vs JEPINUAN vs ONUAN vs KONUAN vs MAINNUAN vs ABBVNUAN vs MRKNUAN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.